Mini-primaquine does help stop people infecting mosquitoes with malaria

February 2, 2018, Liverpool School of Tropical Medicine
This photomicrograph of a blood smear contains a macro- and microgametocyte of the Plasmodium falciparum parasite. Credit: Wikipedia.

A single dose of primaquine is thought to stop people with P. falciparum malaria infecting mosquitoes, which could help bring down malaria transmission. In this Cochrane Review update prepared by an international team of researchers and co-ordinated through the Cochrane infectious Diseases Group (CIDG) based at LSTM, the researchers added recent data to examine this question. Their findings are relevant to the global recommendation by the World Health Organization that mini-primaquine be given to all people unwell with malaria in areas where transmission is low to reduce transmission further.

In these new trials, researchers test infectivity of people by getting mosquitoes to feed on people or their blood and then measuring whether the mosquitoes become infected with malaria. For the currently recommended dose of 0.25 mg/kg, the calculations across 3 trials with 105 participants show the percentage of people infectious 2 to 3 days after treatment is reduced from 14% of people in the control group to 2% in the group. A little later, a week after the treatment had been started, the absolute effect was smaller- with 4% infectious in the and 1% in the primaquine group. This shows that primaquine does reduce transmission-but it may not be to the extent that people had hoped for.

Many potentially infectious people with malaria are asymptomatic, so few would seek treatment. The question of whether a partial reduction in infectiousness for a few days would materially affect the community malaria burden is still unanswered, although modelers have generally concluded that the increased impact would be marginal.

Dr Patricia Graves from James Cook University in Cairns, Australia is first author on the review. She said: "The trials show infectiousness is reduced with low dose primaquine, but the effects were relatively modest and short lived. We also do not know if this then would have any effect on at community level. Given the current evidence, it might be better for policy makers to concentrate on other approaches to help reduce transmission".

Explore further: Cochrane Review on primaquine to prevent malaria transmission

More information: Patricia M Graves et al, Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission, Cochrane Database of Systematic Reviews (2018). DOI: 10.1002/14651858.CD008152.pub5

Related Stories

Cochrane Review on primaquine to prevent malaria transmission

July 3, 2014
Researchers from the Cochrane Infectious Diseases Group, hosted at LSTM, conducted an independent review of the effects of adding a single dose of primaquine (PQ) to malaria treatment to prevent the transmission of the disease.

Low-dose treatment may block malaria transmission

November 14, 2013
Lower doses of the antimalarial drug primaquine are as effective as higher doses in reducing malaria transmission, according to a study published today in Lancet Infectious Diseases by London School of Hygiene & Tropical ...

Discovery of key molecules involved in severe malaria – new target for malaria vaccine

December 4, 2017
Malaria is one of three major infectious diseases affecting approximately 300 million people every year, accounting for about 500,000 deaths, but effective vaccine development has not been successful. Among malaria parasites ...

First in-human vaccine study for malaria caused by Plasmodium vivax

February 26, 2016
Walter Reed Army Institute of Research (WRAIR) researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.

Recommended for you

Scientists gain new insight on how antibodies interact with widespread respiratory virus

February 22, 2018
Scientists have found and characterized the activity of four antibodies produced by the human immune system that target an important protein found in respiratory syncytial virus (RSV), according to new research published ...

Study reveals how kidney disease happens

February 22, 2018
Monash researchers have solved a mystery, revealing how certain immune cells work together to instigate autoimmune kidney disease.

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.